Recomendaciones sobre el tratamiento de la enfermedad fúngica invasiva por Aspergillus spp. y otros hongos filamentosos de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2011
Tóm tắt
Từ khóa
Tài liệu tham khảo
Richardson, 2008, Changing epidemiology of systemic fungal infections, Clin Microbiol Infect., 14, 5, 10.1111/j.1469-0691.2008.01978.x
Marr, 2002, Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors, Blood., 100, 4358, 10.1182/blood-2002-05-1496
Dornbusch, 2009, Invasive fungal infections in children, Pediatr Infect Dis J., 28, 734, 10.1097/INF.0b013e3181b076b1
Zaoutis, 2006, Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000, Pediatrics., 117, e711, 10.1542/peds.2005-1161
Gavalda, 2005, Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study, Clin Infect Dis., 41, 52, 10.1086/430602
Bulpa, 2007, Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease, Eur Respir J., 30, 782, 10.1183/09031936.00062206
Lipke, 2007, Non-decompensated cirrhosis as a risk factor for invasive aspergillosis: a case report and review of the immune dysfunction of cirrhosis, Am J Med Sci., 334, 314, 10.1097/MAJ.0b013e318068d79c
Pasqualotto, 2006, Post-operative aspergillosis, Clin Microbiol Infect., 12, 1060, 10.1111/j.1469-0691.2006.01512.x
Tsiodras, 2008, Fungal infections complicating tumor necrosis factor alpha blockade therapy, Mayo Clin Proc., 83, 181, 10.4065/83.2.181
De Pauw, 2006, Increasing fungal infections in the intensive care unit, Surg Infect (Larchmt)., 7, S93, 10.1089/sur.2006.7.s2-93
Trof, 2007, Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients, Intensive Care Med., 33, 1694, 10.1007/s00134-007-0791-z
Gavalda, 2003, Guidelines for the treatment of infection due to Aspergillus spp, Enferm Infecc Microbiol Clin., 21, 571
Walsh, 2008, Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America, Clin Infect Dis., 46, 327, 10.1086/525258
Maertens, 2010, European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update, Bone Marrow Transplant.
Network NCC. Prevention and treatment of cancer-related infection. NCCN V.2.2009. NCCN Clinical Practice Guidelines in Oncology. 2009 [consultado 2009]. Disponible en: http://www.oralcancerfoundation.org/treatment/pdf/infections-NCCN.pdf.
Mensa, 2009, Treatment of fungal infections in patients with hematologic neoplasia, Med Clin (Barc)., 132, 507, 10.1016/j.medcli.2009.01.008
De la Camara R, Mensa J, Carreras E, Cuenca Estrella M, García Rodríguez JA, Gobernado M, et al. Antifungal prophylaxis in oncohematologic patients: Literature review and recommendations. Med Clin (Barc). 2010;134:222–33.
Cornely, 2007, Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia, N Engl J Med., 356, 348, 10.1056/NEJMoa061094
Ullmann, 2007, Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease, N Engl J Med., 356, 335, 10.1056/NEJMoa061098
Andes, 2009, Antifungal therapeutic drug monitoring: established and emerging indications, Antimicrob Agents Chemother., 53, 24, 10.1128/AAC.00705-08
Glasmacher, 2003, Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients, J Clin Oncol., 21, 4615, 10.1200/JCO.2003.04.052
Wingard, 2010, Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection (IFI) after allo hematopoietic cell transplantation (HCT), Blood., 116, 5111, 10.1182/blood-2010-02-268151
Marks DI KC, Pagliuca A, Ribaud P, Solano C, Heussel CP, Cook G, et al. Voriconazole (VOR) vs itraconazole (ITR) for primary prophylaxis of invasive fungal infection (IFI) in allogeneic hematopoietic cell transplant (HCT) recipients. San Francisco. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2009;M-1249a.
Mattiuzzi G AG, Kantarjian H, Verstovsek S, Cabanillas M, Faderl S, Cooper T, et al. Intravenous voriconazole (IV-VORI) prevents invasive fungal infections (IFI) in patients (pts) with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2011; 104 (Abstract 885).
Vehreschild, 2007, A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML), J Infect., 55, 445, 10.1016/j.jinf.2007.07.003
Mattiuzzi, 2006, Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies, Antimicrob Agents Chemother., 50, 143, 10.1128/AAC.50.1.143-147.2006
Van Burik, 2004, Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation, Clin Infect Dis, 39, 1407, 10.1086/422312
Penack, 2006, Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial, Ann Oncol., 17, 1306, 10.1093/annonc/mdl128
Falagas, 2006, Liposomal amphotericin B as antifungal prophylaxis in bone marrow transplant patients, Am J Hematol., 81, 299, 10.1002/ajh.20535
Rijnders, 2008, Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial, Clin Infect Dis., 46, 1401, 10.1086/586739
Ruiz I, Rovira M, Vázquez L, Martino R, De la Cámara R, Sanz MA, et al. Nebulized liposomal amphotericin B (L-AmB) as antifungal prophylaxis for high-risk hematological patients. San Francisco. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2009;M-1047.
Herbrecht, 2002, Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis, N Engl J Med., 347, 408, 10.1056/NEJMoa020191
Ascioglu, 2002, Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus, Clin Infect Dis., 34, 7, 10.1086/323335
Pascual, 2008, Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes, Clin Infect Dis., 46, 201, 10.1086/524669
Hachem, 2008, Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy, Cancer., 112, 1282, 10.1002/cncr.23311
Walsh, 2001, Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study, Antimicrob Agents Chemother., 45, 3487, 10.1128/AAC.45.12.3487-3496.2001
Cornely, 2007, Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial), Clin Infect Dis., 44, 1289, 10.1086/514341
Viscoli, 2009, An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients, J Antimicrob Chemother., 64, 1274, 10.1093/jac/dkp355
Herbrecht, 2010, Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study, Bone Marrow Transplant., 45, 1227, 10.1038/bmt.2009.334
Maertens, 2004, Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy, Clin Infect Dis., 39, 1563, 10.1086/423381
Caillot, 2003, Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis, Acta Haematol., 109, 111, 10.1159/000069281
Walsh, 2007, Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial, Clin Infect Dis., 44, 2, 10.1086/508774
Kontoyiannis, 2009, Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis, Transpl Infect. Dis, 11, 89, 10.1111/j.1399-3062.2008.00349.x
Ostrosky-Zeichner, 2008, Combination antifungal therapy: a critical review of the evidence, Clin Microbiol Infect., 14, 65, 10.1111/j.1469-0691.2008.01983.x
Cornely, 2010, Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B, J Antimicrob Chemother., 65, 114, 10.1093/jac/dkp397
Smith, 2006, 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline, J Clin Oncol., 24, 3187, 10.1200/JCO.2006.06.4451
Aapro, 2006, EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours, Eur J Cancer., 42, 2433, 10.1016/j.ejca.2006.05.002
Network NCC. Myeloid Growth Factors. NCCN V.1.2010. NCCN Clinical Practice Guidelines in Oncology. 2010 [consultado 2010]. Disponible en: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
Pizzo, 1982, Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia, Am J Med., 72, 101, 10.1016/0002-9343(82)90594-0
Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med. 1989;86:668–72.
Walsh, 1999, Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group, N Engl J Med., 340, 671, 10.1056/NEJM199903113401004
Wingard, 2000, A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group, Clin Infect Dis., 31, 1155, 10.1086/317451
Boogaerts, 2001, Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial, Ann Intern Med., 135, 412, 10.7326/0003-4819-135-6-200109180-00010
Walsh, 2002, Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever, N Engl J Med., 346, 225, 10.1056/NEJM200201243460403
Walsh, 2004, Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia, N Engl J Med., 351, 1391, 10.1056/NEJMoa040446
Maertens, 2005, Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study, Clin Infect Dis., 41, 1242, 10.1086/496927
Cordonnier, 2009, Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial, Clin Infect Dis., 48, 1042, 10.1086/597395
Cuenca-Estrella, 2009, Value of serial quantification of fungal DNA by a real-time PCR-based technique for early diagnosis of invasive Aspergillosis in patients with febrile neutropenia, J Clin Microbiol., 47, 379, 10.1128/JCM.01716-08
Cornely, 2008, Risk factors for breakthrough invasive fungal infection during secondary prophylaxis, J Antimicrob Chemother., 61, 939, 10.1093/jac/dkn027
Cordonnier, 2010, Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study, Haematologica., 95, 1762, 10.3324/haematol.2009.020073
Vigouroux, 2005, Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required, Clin Infect Dis., 40, e35, 10.1086/427752
Chamilos, 2008, Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis, Clin Infect Dis., 47, 503, 10.1086/590004
Van Burik, 2006, Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases, Clin Infect Dis., 42, e61, 10.1086/500212
Greenberg, 2006, Posaconazole as salvage therapy for zygomycosis, Antimicrob Agents Chemother., 50, 126, 10.1128/AAC.50.1.126-133.2006
Reed, 2008, Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis, Clin Infect Dis., 47, 364, 10.1086/589857
Spellberg, 2009, Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis, Antimicrob Agents Chemother., 53, 1225, 10.1128/AAC.00361-09
Spellberg, 2009, Recent advances in the management of mucormycosis: from bench to bedside, Clin Infect Dis., 48, 1743, 10.1086/599105
Perfect, 2003, Voriconazole treatment for less-common, emerging, or refractory fungal infections, Clin Infect Dis., 36, 1122, 10.1086/374557
Raad, 2006, Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions, Clin Infect Dis., 42, 1398, 10.1086/503425
Nucci, 2007, Fusarium infections in immunocompromised patients, Clin Microbiol Rev., 20, 695, 10.1128/CMR.00014-07
Fishman, 2007, Infection in solid-organ transplant recipients, N Engl J Med., 357, 2601, 10.1056/NEJMra064928
Fishman, 2010, Infection in organ transplantation: risk factors and evolving patterns of infection, Infect Dis Clin North Am., 24, 273, 10.1016/j.idc.2010.01.005
Fortun, 2002, Risk factors for invasive aspergillosis in liver transplant recipients, Liver Transpl., 8, 1065, 10.1053/jlts.2002.36239
Gangneux, 2008, Epidemiology of and risk factors for invasive aspergillosis in nonneutropenic patients, Rev Mal Respir., 25, 139, 10.1016/S0761-8425(08)71512-2
Fortun, 2010, Immunosuppressive therapy and infection after kidney transplantation, Transpl Infect Dis., 12, 397, 10.1111/j.1399-3062.2010.00526.x
Lewis, 2009, Invasive aspergillosis in glucocorticoid-treated patients, Med Mycol., 47, S271, 10.1080/13693780802227159
Marik, 2006, Fungal infections in solid organ transplantation, Expert Opin Pharmacother., 7, 297, 10.1517/14656566.7.3.297
Maschmeyer, 2009, Invasive mould infections: a multi-disciplinary update, Med Mycol., 47, 571, 10.1080/13693780902946559
Morgan, 2005, Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program, Med Mycol., 43, S49, 10.1080/13693780400020113
Neofytos, 2010, Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients, Transpl Infect Dis., 12, 220, 10.1111/j.1399-3062.2010.00492.x
Pappas, 2010, Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET), Clin Infect Dis., 50, 1101, 10.1086/651262
Paterson, 1999, Invasive aspergillosis in transplant recipients, Medicine (Baltimore)., 78, 123, 10.1097/00005792-199903000-00003
Patterson, 2000, Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group, Medicine (Baltimore)., 79, 250, 10.1097/00005792-200007000-00006
Person, 2010, Fungal infections in transplant and oncology patients, Infect Dis Clin North Am., 24, 439, 10.1016/j.idc.2010.01.002
Silveira, 2007, Fungal infections in solid organ transplantation, Med Mycol., 45, 305, 10.1080/13693780701200372
Singh, 2005, Invasive aspergillosis in organ transplant recipients: new issues in epidemiologic characteristics, diagnosis, and management, Med Mycol., 43, S267, 10.1080/13693780500051984
Singh, 2009, Invasive aspergillosis in solid organ transplant recipients, Am J Transplant., 9, S180, 10.1111/j.1600-6143.2009.02910.x
Singh, 2006, Late-onset invasive aspergillosis in organ transplant recipients in the current era, Med Mycol., 44, 445, 10.1080/13693780600684494
White, 2005, Aspergillus pulmonary infections in transplant recipients, Clin Chest Med., 26, 661, 10.1016/j.ccm.2005.06.007
Husain, 2003, Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi, Clin Infect Dis., 37, 221, 10.1086/375822
Osawa, 2007, Risk factors for invasive aspergillosis in living donor liver transplant recipients, Liver Transpl., 13, 566, 10.1002/lt.21099
Fortun, 2003, Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients, J Antimicrob Chemother., 52, 813, 10.1093/jac/dkg450
Singh, 2001, Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy, Transplantation., 71, 910, 10.1097/00007890-200104150-00016
Heinz, 2008, Caspofungin for treatment of invasive aspergillus infections, Mycoses., 51, 47, 10.1111/j.1439-0507.2008.01528.x
Singh, 2006, Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study, Transplantation., 81, 320, 10.1097/01.tp.0000202421.94822.f7
Singh, 2006, Invasive aspergillosis in the recipients of liver retransplantation, Liver Transpl., 12, 1205, 10.1002/lt.20756
Gavalda, 2007, Infection in lung transplantation, Enferm Infecc Microbiol Clin., 25, 639
Grossi, 2000, Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients, Transplantation., 70, 112
Marino, 2010, Prophylactic antifungal agents used after lung transplantation, Ann Pharmacother., 44, 546, 10.1345/aph.1M377
Monforte, 2001, Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors, J Heart Lung Transplant., 20, 1274, 10.1016/S1053-2498(01)00364-3
Singh, 2005, Aspergillus infections in transplant recipients, Clin Microbiol Rev., 18, 44, 10.1128/CMR.18.1.44-69.2005
Cahill, 1997, Aspergillus airway colonization and invasive disease after lung transplantation, Chest., 112, 1160, 10.1378/chest.112.5.1160
Helmi, 2003, Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients, Chest., 123, 800, 10.1378/chest.123.3.800
Husni, 1998, Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients, Clin Infect Dis., 26, 753, 10.1086/514599
Linden, 2003, Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B, Clin Infect Dis., 37, 17, 10.1086/375219
Chandrasekar, 2005, Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients, Clin Infect Dis., 40, S392, 10.1086/429333
Kleinberg, 2005, Aspergillosis in the CLEAR outcomes trial: working toward a real-world clinical perspective, Med Mycol., 43, S289, 10.1080/13693780400025237
Denning, 2002, Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis, Clin Infect Dis., 34, 563, 10.1086/324620
Fortun, 2003, Voriconazole in the treatment of invasive mold infections in transplant recipients, Eur J Clin Microbiol Infect Dis., 22, 408, 10.1007/s10096-003-0960-0
Wieland, 2005, Superiority of voriconazole over amphotericin B in the treatment of invasive aspergillosis after heart transplantation, J Heart Lung Transplant., 24, 102, 10.1016/j.healun.2003.10.014
Baden, 2003, Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy, Transplantation., 76, 1632, 10.1097/01.TP.0000089109.42239.75
Veroux, 2007, Voriconazole in the treatment of invasive aspergillosis in kidney transplant recipients, Transplant Proc., 39, 1838, 10.1016/j.transproceed.2007.05.012
Schwartz, 2005, Improved outcome in central nervous system aspergillosis, using voriconazole treatment, Blood., 106, 2641, 10.1182/blood-2005-02-0733
Groetzner, 2008, Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation, J Heart Lung Transplant., 27, 1, 10.1016/j.healun.2007.10.002
Maertens, 2010, Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry, BMC Infect Dis., 10, 182, 10.1186/1471-2334-10-182
Winkler, 2010, Caspofungin for post solid organ transplant invasive fungal disease: results of a retrospective observational study, Transpl Infect Dis., 12, 230, 10.1111/j.1399-3062.2009.00490.x
Denning, 2006, Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis, J Infect., 53, 337, 10.1016/j.jinf.2006.03.003
Antachopoulos, 2007, Fungal infections in primary immunodeficiencies, Eur J Pediatr., 166, 1099, 10.1007/s00431-007-0527-7
Alexander, 2008, Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant, Transplantation., 86, 791, 10.1097/TP.0b013e3181837585
Saad, 2006, Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants, Pharmacotherapy., 26, 1730, 10.1592/phco.26.12.1730
Leather, 2006, Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients, Biol Blood Marrow Transplant., 12, 325, 10.1016/j.bbmt.2005.10.022
Mathis, 2004, Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases, Transplant Proc., 36, 2708, 10.1016/j.transproceed.2004.09.043
Sable, 2002, Safety and tolerability of caspofungin acetate in the treatment of fungal infections, Transpl Infect Dis., 4, 25, 10.1034/j.1399-3062.2002.01004.x
Cuenca-Estrella, 2009, Incidence of zygomycosis in transplant recipients, Clin Microbiol Infect., 15, 37, 10.1111/j.1469-0691.2009.02978.x
Sole, 2009, Fungal infections after lung transplantation, Curr Opin Pulm Med., 15, 243, 10.1097/MCP.0b013e328326f410
Singh, 2009, Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome, J Infect Dis., 200, 1002, 10.1086/605445
Almyroudis, 2006, Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature, Am J Transplant., 6, 2365, 10.1111/j.1600-6143.2006.01496.x
Stelzmueller, 2008, Zygomycosis and other rare filamentous fungal infections in solid organ transplant recipients, Transpl Int., 21, 534, 10.1111/j.1432-2277.2008.00657.x
Cooke, 2010, Successful treatment of pulmonary zygomycosis in two transplant recipients with liposomal amphotericin B and partial surgical resection followed by posaconazole, Mycoses., 53, 163, 10.1111/j.1439-0507.2008.01666.x
Sun, 2009, Pulmonary zygomycosis in solid organ transplant recipients in the current era, Am J Transplant., 9, 2166, 10.1111/j.1600-6143.2009.02754.x
Sun, 2010, Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients, Transplantation., 90, 85, 10.1097/TP.0b013e3181dde8fc
Gibbs, 2005, Liposomal amphotericin B: clinical experience and perspectives, Expert Rev Anti Infect Ther., 3, 167, 10.1586/14787210.3.2.167
Reed, 2006, Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis, Antimicrob Agents Chemother., 50, 3968, 10.1128/AAC.01065-06
Ibrahim, 2006, Deferiprone iron chelation as a novel therapy for experimental mucormycosis, J Antimicrob Chemother., 58, 1070, 10.1093/jac/dkl350
Spellberg, 2005, Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice, Antimicrob Agents Chemother., 49, 830, 10.1128/AAC.49.2.830-832.2005
Gonzalez, 1997, Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor, Clin Infect Dis., 24, 192, 10.1093/clinids/24.2.192
Gil-Lamaignere, 2005, Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes, J Infect Dis., 191, 1180, 10.1086/428503
Troke, 2008, Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients, Antimicrob Agents Chemother., 52, 1743, 10.1128/AAC.01388-07
Rodriguez-Tudela, 2009, Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases, Med Mycol., 47, 359, 10.1080/13693780802524506
Ruiz-Camps, 2010, Recommendations of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the prevention of invasive fungal infection due to filamentous fungi, Enferm Infecc Microbiol Clin., 28
Pappas, 2009, Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America, Clin Infect Dis., 48, 503, 10.1086/596757
Cruciani, 2006, Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis, Liver Transpl., 12, 850, 10.1002/lt.20690
Playford EG, Webster AC, Sorell TC, Craig JC. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev. 2004:CD004291.
Singh, 2004, Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design, Clin Infect Dis., 39, S200, 10.1086/421957
Pappas, 2006, Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study, Am J Transplant., 6, 386, 10.1111/j.1600-6143.2005.01176.x
San Juan R, Torre-Cisneros J, Ramos A, Llinares P, Cordero E, Fortún J, et al. Role of prophylaxis with fluconazole in the prevention of early invasive fungal infection (IFI) in low risk liver transplant recipients (ITR): Data from the RESITRA-REIPI Prospective Multicenter Cohort ICCAC. 2009;Abstract K-981.
Singhal, 2000, Targeted prophylaxis with amphotericin B lipid complex in liver transplantation, Liver Transpl., 6, 588, 10.1053/jlts.2000.7572
Castroagudin, 2005, Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients, Transplant Proc., 37, 3965, 10.1016/j.transproceed.2005.10.043
Reed, 2007, Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients, Liver Transpl., 13, 1743, 10.1002/lt.21331
Hadley, 2009, Outcomes of antifungal prophylaxis in high-risk liver transplant recipients, Transpl Infect Dis., 11, 40, 10.1111/j.1399-3062.2008.00361.x
Husain, 2006, Voriconazole prophylaxis in lung transplant recipients, Am J Transplant., 6, 3008, 10.1111/j.1600-6143.2006.01548.x
Cadena, 2009, Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness, Am J Transplant., 9, 2085, 10.1111/j.1600-6143.2009.02734.x
Fortun, 2009, Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients, Transplantation., 87, 424, 10.1097/TP.0b013e3181932e76
Husain, 2006, Variation in antifungal prophylaxis strategies in lung transplantation, Transpl Infect Dis., 8, 213, 10.1111/j.1399-3062.2006.00156.x
Calvo, 1999, Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group, Chest., 115, 1301, 10.1378/chest.115.5.1301
Gavalda, 2005, Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis, Antimicrob Agents Chemother., 49, 3028, 10.1128/AAC.49.7.3028-3030.2005
Monforte, 2010, Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation, J Heart Lung Transplant., 29, 523, 10.1016/j.healun.2009.11.603
Palmer, 2001, Safety of aerosolized amphotericin B lipid complex in lung transplant recipients, Transplantation., 72, 545, 10.1097/00007890-200108150-00036
Drew, 2004, Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients, Transplantation., 77, 232, 10.1097/01.TP.0000101516.08327.A9
Borro, 2008, Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation, Transplant Proc., 40, 3090, 10.1016/j.transproceed.2008.09.020
Lumbreras, 1995, Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome, Clin Infect Dis., 20, 514, 10.1093/clinids/20.3.514
Michalak, 2005, Infectious complications after simultaneous pancreas-kidney transplantation, Transplant Proc., 37, 3560, 10.1016/j.transproceed.2005.09.078
Montoya, 2001, Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center, Clin Infect Dis., 33, 629, 10.1086/322733
Munoz, 2004, Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis, Am J Transplant., 4, 636, 10.1111/j.1600-6143.2004.00390.x
Gurgui, 2007, Infection in heart transplantation, Enferm Infecc Microbiol Clin., 25, 587
Garrido, 2006, A review of critical periods for opportunistic infection in the new transplantation era, Transplantation., 82, 1457, 10.1097/01.tp.0000245676.43979.86
Gabardi, 2007, Invasive fungal infections and antifungal therapies in solid organ transplant recipients, Transpl Int., 20, 993, 10.1111/j.1432-2277.2007.00511.x
Safdar, 2005, Predictors and outcomes of candiduria in renal transplant recipients, Clin Infect Dis., 40, 1413, 10.1086/429620
Meersseman, 2007, Invasive aspergillosis in the intensive care unit, Clin Infect Dis., 45, 205, 10.1086/518852
Denning, 2004, Aspergillosis in “nonimmunocompromised” critically ill patients, Am J Respir Crit Care Med., 170, 580, 10.1164/rccm.2407004
Anaissie, 2008, A bad bug takes on a new role as a cause of ventilator-associated pneumonia, Am J Respir Crit Care Med., 177, 1, 10.1164/rccm.200710-1482ED
Garnacho-Montero, 2005, Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome, Crit Care., 9, R191, 10.1186/cc3488
Meersseman, 2004, Invasive aspergillosis in critically ill patients without malignancy, Am J Respir Crit Care Med., 170, 621, 10.1164/rccm.200401-093OC
Vandewoude, 2006, Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients, Crit Care., 10, R31, 10.1186/cc4823
Dimopoulos, 2003, Disseminated aspergillosis in intensive care unit patients: an autopsy study, J Chemother., 15, 71, 10.1179/joc.2003.15.1.71
Vandewoude, 2004, Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence, J Hosp Infect., 56, 269, 10.1016/j.jhin.2004.01.006
Vandewoude, 2004, Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality, Acta Clin Belg., 59, 251, 10.1179/acb.2004.037
Maravi-Poma, 2004, Outbreak of gastric mucormycosis associated with the use of wooden tongue depressors in critically ill patients, Intensive Care Med., 30, 724, 10.1007/s00134-003-2132-1
Lionakis, 2004, Fusarium infections in critically ill patients, Semin Respir Crit Care Med., 25, 159, 10.1055/s-2004-824900
Groll, 2001, Uncommon opportunistic fungi: new nosocomial threats, Clin Microbiol Infect., 7, 8, 10.1111/j.1469-0691.2001.tb00005.x
Prodanovic, 2007, Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series, BMC Gastroenterol., 7, 2, 10.1186/1471-230X-7-2
Rello, 1998, Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: report of eight cases and review, Clin Infect Dis., 26, 1473, 10.1086/517672
Ader, 2005, Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen, Clin Microbiol Infect., 11, 427, 10.1111/j.1469-0691.2005.01143.x
Meersseman, 2008, Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients, Am J Respir Crit Care Med., 177, 27, 10.1164/rccm.200704-606OC
Diamond, 1983, Inhibition of monocyte-mediated damage to fungal hyphae by steroid hormones, J Infect Dis., 147, 160, 10.1093/infdis/147.1.160
Schaffner, 1985, Therapeutic concentrations of glucocorticoids suppress the antimicrobial activity of human macrophages without impairing their responsiveness to gamma interferon, J Clin Invest., 76, 1755, 10.1172/JCI112166
Ng, 1994, Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis, Microbiology, 140, 2475, 10.1099/13500872-140-9-2475
Hartemink, 2003, Immunoparalysis as a cause for invasive aspergillosis?, Intensive Care Med., 29, 2068, 10.1007/s00134-003-1778-z
Lederer, 1999, The effects of injury on the adaptive immune response, Shock., 11, 153, 10.1097/00024382-199903000-00001
Garnacho-Montero, 2006, A validated clinical approach for the management of aspergillosis in critically ill patients: ready, steady, go!, Crit Care., 10, 132, 10.1186/cc4860
Lewis, 2007, Pharmacodynamic implications for use of antifungal agents, Curr Opin Pharmacol., 7, 491, 10.1016/j.coph.2007.05.004
Walsh, 1998, Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases, Clin Infect Dis., 26, 1383, 10.1086/516353
Kartsonis, 2005, Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study, J Infect., 50, 196, 10.1016/j.jinf.2004.05.011
Candoni, 2005, Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies, Eur J Haematol., 75, 227, 10.1111/j.1600-0609.2005.00500.x
Steinbach, 2005, Pediatric aspergillosis: disease and treatment differences in children, Pediatr Infect Dis J., 24, 358, 10.1097/01.inf.0000157218.37603.84
Dotis, 2004, Osteomyelitis due to Aspergillus spp. in patients with chronic granulomatous disease: comparison of Aspergillus nidulans and Aspergillus fumigatus, Int J Infect Dis., 8, 103, 10.1016/j.ijid.2003.06.001
Rubio, 2009, Increasing incidence of invasive aspergillosis in pediatric hematology oncology patients over the last decade: a retrospective single centre study, J Pediatr Hematol Oncol., 31, 642, 10.1097/MPH.0b013e3181acd956
Panagopoulou, 2002, Trichosporon asahii: an unusual cause of invasive infection in neonates, Pediatr Infect Dis J., 21, 169, 10.1097/00006454-200202000-00018
Zaoutis, 2007, Zygomycosis in children: a systematic review and analysis of reported cases, Pediatr Infect Dis J., 26, 723, 10.1097/INF.0b013e318062115c
Segal, 2006, Current approaches to diagnosis and treatment of invasive aspergillosis, Am J Respir Crit Care Med., 173, 707, 10.1164/rccm.200505-727SO
Park, 2009, Innate immunity to Aspergillus species, Clin Microbiol Rev., 22, 535, 10.1128/CMR.00014-09
Abbasi, 1999, Aspergillosis in children with cancer: A 34-year experience, Clin Infect Dis., 29, 1210, 10.1086/313445
el-Mahallawy, 2002, A prospective study on fungal infection in children with cancer, J Med Microbiol., 51, 601, 10.1099/0022-1317-51-7-601
Lin, 2001, Aspergillosis case-fatality rate: systematic review of the literature, Clin Infect Dis., 32, 358, 10.1086/318483
Abrams, 2000, Opportunistic infections and other clinical manifestations of HIV disease in children, Pediatr Clin North Am., 47, 79, 10.1016/S0031-3955(05)70196-6
Guillen, 2010, Opportunistic infections and organ-specific diseases in HIV-1-infected children: a cohort study (1990–2006), HIV Med., 11, 245, 10.1111/j.1468-1293.2009.00768.x
Goetghebuer, 2009, Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants, AIDS., 23, 597, 10.1097/QAD.0b013e328326ca37
Roman, 2008, Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation, Pediatr Blood Cancer., 50, 325, 10.1002/pbc.21239
Sole, 2005, Aspergillus infections in lung transplant recipients: risk factors and outcome, Clin Microbiol Infect., 11, 359, 10.1111/j.1469-0691.2005.01128.x
Roilides, 2009, Invasive zygomycosis in neonates and children, Clin Microbiol Infect., 15, 50, 10.1111/j.1469-0691.2009.02981.x
Dehority, 2009, Zygomycetes infections in pediatric hematology oncology patients: a case series and review of the literature, J Pediatr Hematol Oncol., 31, 911, 10.1097/MPH.0b013e3181bbc516
Cortez, 2008, Infections caused by Scedosporium spp, Clin Microbiol Rev., 21, 157, 10.1128/CMR.00039-07
Kaufman, 2004, Fungal infection in the very low birthweight infant, Curr Opin Infect Dis., 17, 253, 10.1097/00001432-200406000-00014
Karlsson, 2009, Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies, Antimicrob Agents Chemother., 53, 935, 10.1128/AAC.00751-08
Pasqualotto, 2008, New and emerging treatments for fungal infections, J Antimicrob Chemother., 61, i19, 10.1093/jac/dkm428
Neely, 2009, Pharmacokinetics and safety of caspofungin in older infants and toddlers, Antimicrob Agents Chemother., 53, 1450, 10.1128/AAC.01027-08
Saez-Llorens, 2009, Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age, Antimicrob Agents Chemother., 53, 869, 10.1128/AAC.00868-08
Garnock-Jones, 2009, Caspofungin: in pediatric patients with fungal infections, Paediatr Drugs., 11, 259, 10.2165/00148581-200911040-00005
Walsh, 2002, Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children, Pediatr Infect Dis J., 21, 240, 10.1097/00006454-200203000-00015
Zaoutis, 2009, A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients, Pediatrics., 123, 877, 10.1542/peds.2008-1158
Wiley, 2005, Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections, Pediatr Infect Dis J., 24, 167, 10.1097/01.inf.0000153183.51258.b8
Maertens, 2010, A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia, Pediatr Infect Dis J., 29, 415, 10.1097/INF.0b013e3181da2171
Segal, 2005, Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection, Clin Infect Dis., 40, 1648, 10.1086/430068
Steinbach, 2006, Mycoses in pediatric patients, Infect Dis Clin North Am., 20, 663, 10.1016/j.idc.2006.06.006